^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 amplification

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    Entrez ID:
    7157
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    GLI1, CDK4, and MDM2 Co-Amplification Gastric Plexiform Fibromyxoma: A Case Report and Literature Review. (PubMed, Genes Chromosomes Cancer)
    No recurrence was observed during the follow-up period of 8 months. This study aims to improve our understanding of PF by analyzing the clinicopathological characteristics of this case, including immunohistochemical (IHC) and genetic examination, and reviewing relevant literature.
    Review • Journal
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • CD34 (CD34 molecule) • GLI1 (GLI Family Zinc Finger 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • STAT6 (Signal transducer and activator of transcription 6)
    |
    TP53 mutation • CDK4 amplification • TP53 amplification • CDK4 mutation
    1year
    Hepatitis B Virus X Protein Induces Reactive Oxygen Species Generation via Activation of p53 in Human Hepatoma Cells. (PubMed, Biomolecules)
    Additionally, HBx variants with Ser-101 increased p53 and ROS levels, whereas variants with Pro-101 did not. These dual mechanisms of HBx-induced ROS generation are likely significant in the pathogenesis of HBV and may contribute to liver diseases, including hepatocellular carcinoma.
    Journal
    |
    CAT (Catalase)
    |
    TP53 expression • TP53 amplification
    1year
    Re-evaluation of the concept of basaloid follicular hamartoma associated with naevoid basal cell carcinoma syndrome: a morphological, immunohistochemical and molecular study. (PubMed, Pathology)
    Targeted next-generation sequencing suggested that MYCN and GLI2/3 amplifications and TP53 mutations might be involved in progression of these follicular tumours to BCC. Our study confirms the high prevalence of BFH, representing up to 24% of skin tumours in NBCCS and potentially being BCC precursors.
    Journal
    |
    TP53 (Tumor protein P53) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • GLI2 (GLI Family Zinc Finger 2)
    |
    TP53 mutation • TP53 amplification
    1year
    This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=267, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    1year
    A case of esophageal squamous cell carcinoma with epidermization showing a unique morphology. (PubMed, Clin J Gastroenterol)
    Cancer genome analysis revealed mutations in TP53 as well as amplification of MYC, FGFR1, chromosome 7, and chromosome 20q. This case suggests that epidermoid metaplasia caused by chronic irritation from an esophageal stricture may have been exacerbated by the dilation procedure.
    Journal
    |
    TP53 (Tumor protein P53) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    TP53 mutation • TP53 amplification
    1year
    Molecular Analysis of High-Grade Serous Ovarian Carcinoma Exhibiting Low-Grade Serous Carcinoma and Serous Borderline Tumor. (PubMed, Curr Issues Mol Biol)
    After surgery, TC (Paclitaxel + Carbopratin) + bevacizumab therapy was administered as adjuvant chemotherapy followed by bevacizumab as maintenance therapy. DNA methylation analysis did not show differentially methylated regions. This case suggests that SBT and LGSC may transform into HGSC via p53 dysfunction due to MDM2 amplification.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type • KRAS G12V • MDM2 amplification • KRAS G12 • TP53 amplification
    |
    Avastin (bevacizumab) • paclitaxel
    1year
    CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma. (PubMed, NPJ Genom Med)
    Additionally, we observed recurring promoter swapping events involving the regulatory regions of the FRS2, PLEKHA5, and TP53 genes. These events resulted in ectopic expression of partner genes, with the ELF1 gene being upregulated by the FRS2 and TP53 promoter regions in two distinct cases.
    Journal
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2) • ELF1 (E74 Like ETS Transcription Factor 1)
    |
    MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification • TP53 amplification
    1year
    Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder (clinicaltrials.gov)
    P2, N=103, Recruiting, Boehringer Ingelheim | N=155 --> 103
    Enrollment change • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 wild-type • MDM2 amplification • TP53 amplification
    |
    brigimadlin (BI 907828)
    1year
    TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases. (PubMed, Heliyon)
    Gene signatures, such as TP53 or EGFR amplification, were associated with worse survival in patients diagnosed with NSCLC-BM. These valuable findings may shed light on new strategies for the prognostic assessment of specific patient groups.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • LRP1B (LDL Receptor Related Protein 1B) • RNF43 (Ring Finger Protein 43)
    |
    TP53 mutation • EGFR amplification • RNF43 mutation • TP53 amplification
    over1year
    Clinicopathological and molecular characteristics of pediatric gliomas: analysis of 111 cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    There are significant differences in clinical manifestations, pathological characteristics, molecular variations, and prognosis between the pDLGG, CAG and pDHGG groups. The integrated diagnosis combining histology and molecular features is of great importance for the accurate diagnosis and treatment of pediatric gliomas.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • ATRX (ATRX Chromatin Remodeler) • KIAA1549 • H3-3A (H3.3 Histone A)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • KIAA1549-BRAF fusion • BRAF fusion • TP53 amplification
    over1year
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=119, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    over1year
    ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • MDM4 (The mouse double minute 4) • GDF15 (Growth differentiation factor 15) • CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification
    |
    paclitaxel • sulanemadlin (ALRN-6924)